Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

Amgen's first-to-market KRAS inhibitor Lumakras has so far failed to live up to once-lofty sales expectations, but a new FDA approval could lend momentum to its growth. The US regulator has ...

Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic ...

Lumakras, primarily known for lung cancer treatment, became the first FDA-approved KRASG12C inhibitor in 2021 for non-small ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...